Frontlight ResearchEarly access
CompletedPhase 4
Pericapsular Nerve Group Block Chemical Neurolysis in Advanced Hip Osteoarthritis
Key facts
- Who runs it
- Poznan University of Medical Sciences
- Where
- Poland1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 100 people enrolled
- Started
- 17 Oct 2023
- Ended
- 14 Jan 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- 0.9%sodium chloride
- 95% ethanol
- Record updated
- 21 January 2025
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients of the Pain Treatment Clinic of the Transfiguration of Jesus Clinical Hospital of the Medical University of Poznań will be qualified for the study
- patients with coxarthrosis or gonarthrosis who failed to achieve satisfactory pain control (NRS>3) despite the use of NSAIDs, Paracetamol, and co-analgetics
- Age of patients: from 18 to 110 years of age
- Caucasian patients can give informed, complete, written consent
Who cannot take part
- suspected or diagnosed opioid dependence syndrome
- active cancer
- dementia
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
PENG neurolysis in advanced osteoarthritis of the hip joint.
The 2 groups in the trial
- sham PENG blockExisting treatment, for comparison
PENG block - 20ml 0,9% normal saline
Treatment: 0.9%sodium chloride
- PENG neurolysisExisting treatment, for comparison
PENG neurolysis with 5ml 95% ethanol
Treatment: 95% ethanol
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Impact of the Pericapsular Nerve Group Block (PENG) Chemical Neurolysis on the Quality of Life of Patients with Advanced Hip Osteoarthritis. a Randomized, Prospective Double-blinded Clinical Trial.
- Publications
- Record updated
- 21 January 2025